Suppr超能文献

[糖尿病微血管病变]

[Diabetic microangiopathy].

作者信息

Standl R

机构信息

III. Medizinische Abteilung, Städtischen Krankenhauses München-Schwabing.

出版信息

Z Gesamte Inn Med. 1993 Mar;48(3):140-9.

PMID:8475638
Abstract

On the whole, diabetic microangiopathy can be understood as the clinical renal-retinal syndrome. About 10% of all diabetics die of end-stage renal failure, more frequent in IDDM. With an incidence of 14% diabetic retinopathy is one of the major causes of blindness in adulthood. In the non-proliferative state, the pathological changes are limited to the retina, whereas the alterations affect both retina and vitreous in the proliferative state. Photocoagulation is the treatment of choice. If photocoagulatory treatment is not possible because of cataract, vitreous surgery (pars-plana vitrectomy) could improve visual prognosis. The clinical features hypertension, proteinuria and finally renal failure define the term "diabetic nephropathy". The increased intraglomerular pressure is the main pathological alteration of incipient nephropathy. Microalbuminuria essentially determines the prognosis: in IDDM it concerns the incidence of a manifest nephropathy, in NIDDM the excessively increased incidence of cardiovascular mortality. Sonographically, the kidneys are large with bright and wide parenchyma. Along with the development of end-stage renal disease the kidney size diminishes. According to Mogensen, nephropathy is divided into five stages: Stage 1, the early stage, is defined by hypertrophy and hyperfiltration. Stage 2 shows incipient structural changes without any clinical findings. Stage 3 is characterised by persistent microalbuminuria. Stage 4 leads to increasing renal failure and stage 5 to end-stage renal disease and the necessity of dialysis treatment. Incipient nephropathy demands a strict treatment of both hypertension and diabetes. In the meantime, ACE inhibitors are the treatment of choice. In case of dialysis treatment continuous ambulant peritoneal dialysis (CAPD) is usually preferred.

摘要

总体而言,糖尿病微血管病变可被理解为临床肾 - 视网膜综合征。所有糖尿病患者中约10%死于终末期肾衰竭,在胰岛素依赖型糖尿病(IDDM)中更为常见。糖尿病视网膜病变的发病率为14%,是成年人失明的主要原因之一。在非增殖期,病理变化仅限于视网膜,而在增殖期,病变则影响视网膜和玻璃体。光凝治疗是首选治疗方法。如果因白内障而无法进行光凝治疗,玻璃体手术(平坦部玻璃体切除术)可改善视力预后。高血压、蛋白尿以及最终的肾衰竭等临床特征定义了“糖尿病肾病”这一术语。肾小球内压力升高是早期肾病的主要病理改变。微量白蛋白尿在很大程度上决定预后:在IDDM中,它关乎显性肾病的发病率,在非胰岛素依赖型糖尿病(NIDDM)中,它关乎心血管死亡率的过度升高。超声检查显示,肾脏增大,肾实质明亮且增宽。随着终末期肾病的发展,肾脏大小会缩小。根据莫根森的分类,肾病分为五个阶段:1期为早期,其特征为肥大和超滤过;2期显示初期结构改变但无任何临床症状;3期的特征是持续微量白蛋白尿;4期导致肾衰竭加重,5期为终末期肾病,需要进行透析治疗。早期肾病需要严格治疗高血压和糖尿病。同时,血管紧张素转换酶(ACE)抑制剂是首选治疗药物。在进行透析治疗时,通常首选持续非卧床腹膜透析(CAPD)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验